SCHEMBL13638419

SCHEMBL13638419

C=C1CC(Nc2nccc(-c3ccc(OCCOC)s3)n2)CC(C)(C)N1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 7/20 0.36
CDK2 P24941 7/20 0.36
CDK1 P06493 6/20 0.36
CCNA2 P20248 6/20 0.36
CCNE1 P24864 3/20 0.36
CCND3 P30281 3/20 0.36
CDK6 Q00534 3/20 0.36
CCNB1 P14635 4/20 0.34
CCND1 P24385 4/20 0.34
CCNA1 P78396 4/20 0.34
MAPK1 P28482 2/20 0.34
MKNK2 Q9HBH9 1/20 0.33
IKBKB O14920 1/20 0.32
CHUK O15111 1/20 0.32
IKBKG Q9Y6K9 1/20 0.32
EIF2AK2 P19525 2/20 0.32
GSK3B P49841 1/20 0.31
JAK2 O60674 1/20 0.31
JAK1 P23458 1/20 0.31
TYK2 P29597 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13638463 0.92 CDK4 (0.35) CDK4CDK2CDK1CCNA2CCNE1
SCHEMBL13638464 0.89 AKT3 (0.35) CDK4CDK2CDK1CCNA2CCNE1
SCHEMBL3476364 0.87 CDK4 (0.37) CDK4CDK2CDK1CCNA2CCNE1
SCHEMBL13638560 0.86 MAPK8 (0.39) CDK4CDK2CDK1CCNA2CCNB1
SCHEMBL13638456 0.86 IKBKB (0.42) CDK4CDK2CDK1CCNA2CCNE1
SCHEMBL13638454 0.82 CDK4 (0.36) CDK4CDK2CDK1CCNA2CCNE1
SCHEMBL14612785 0.82 IKBKB (0.37) CDK4CDK2CDK1CCNA2CCNE1
SCHEMBL13638579 0.81 SRC (0.35) CDK4CDK2CDK1CCNA2CCNE1
SCHEMBL14612804 0.81 MKNK1 (0.39) MKNK2IKBKBCHUKEIF2AK2GSK3B
SCHEMBL13638429 0.80 IKBKB (0.34) CDK4CDK2CDK1CCNA2CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615562-B2 Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents NOVARTIS AG (CH) 2009-11-10 US disclosed
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use NOVARTIS AG (CH) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use TPMT, IKBKB, CHUK CDK4 681/4885CDK2 77/4885CDK1 555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.